FDA Grants HUTCHMED's Sovleplenib Second Orphan Status, This Time for AIHA
The FDA status carries 7 years of US market exclusivity if the oral drug is approved, and HUTCHMED keeps all worldwide rights.
HUTCHMED, which develops and sells targeted cancer and immunology drugs, said Thursday the FDA granted Orphan Drug Designation to its oral drug sovleplenib for autoimmune hemolytic anemia. It is the drug's second orphan designation, following one for primary immune thrombocytopenia (ITP) announced in October 2026.
What orphan status offers
The FDA program covers drugs for rare conditions affecting fewer than 200,000 people in the United States. If sovleplenib wins approval for the designated indication, it becomes eligible for 7 years of US market exclusivity, the company said.
The designation also brings tax credits for qualified clinical trials, user fee waivers under the Prescription Drug User Fee Act, and specialized FDA guidance during clinical development.
HUTCHMED cited an estimated prevalence of 17 per 100,000 adults for autoimmune hemolytic anemia (AIHA), in which antibodies lead to destruction of red blood cells. It put the death rate at 8-11%. The warm form of the disease accounts for about 75-80% of adult cases.
A Syk inhibitor with no partner
Sovleplenib is a selective, once-daily oral inhibitor of spleen tyrosine kinase, or Syk, which the company describes as an established target in autoimmune disorders and certain B-cell lymphomas. HUTCHMED said it retains all rights to the drug worldwide.
The company's marketed drugs include savolitinib, fruquintinib and surufatinib, sold in China, according to its annual report. Its market value was US$2.4 billion.
Chinese reviews under way
In China, new drug applications for sovleplenib in primary ITP and warm AIHA are under review by the National Medical Products Administration. They rest on positive data from the pivotal ESLIM-01 and ESLIM-02 trials in China, respectively.
The company's release is dated Thursday, November 5, 2026, and was furnished to the SEC on Form 6-K.
Sources
- Form 6-K — Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval — — Marks the second US FDA Orphan Drug Designation for sovleplenib, following its re — SEC EDGAR
- https://www.sec.gov/Archives/edgar/data/1648257/000164825726000070/hcm-ex99d1.htm — sec.gov
- HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia | Nasdaq — nasdaq.com
- HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug — globenewswire.com
- HUTCHMED (AIM:HCM) Stock May Look Rich As FDA Orphan Drug News Lands — Yahoo Finance